Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors

This study compared dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, and dipeptidyl peptidase-4 inhibitors (DPP-4i) with regard to cardiovascular (CV) event incidence and direct medical costs during type 2 diabetes treatment. A retrospective cohort study was conducted using national healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Seong, Jong-Mi, Kim, Jong Joo, Kim, Hae Jin, Sohn, Hyun Soon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505976/
https://www.ncbi.nlm.nih.gov/pubmed/34650428
http://dx.doi.org/10.3389/fphar.2021.689885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505976/
https://www.ncbi.nlm.nih.gov/pubmed/34650428
http://dx.doi.org/10.3389/fphar.2021.689885

Ejemplares similares